AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15314950 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK mixture
Number of subjects: 0
Study 15314950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10475511 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing products containing naturally-derived grit
Number of subjects: 16
Study 10475511 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing products containing synthetic grit
Number of subjects: 16
Study 7675373 — intervention group
Group type: EXPERIMENTAL
Intervention: specially‐formulated, carbohydrate‐rich beverage
Number of subjects: 24
Study 7675373 — intervention group
Group type: COMPARATOR
Intervention: isocaloric placebo interventions
Number of subjects: 24
Study 2123065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild induction chemotherapy in patients aged greater than or equal to 70 and/or with concurrent nonhematologic disorders (28 patients)
Number of subjects: 103
Study 2123065 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional induction chemotherapy in eligible patients (52 patients)
Number of subjects: 103
Study 2123065 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone in patients not suitable for induction chemotherapy (23 patients)
Number of subjects: 103
Study 7382828 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin (biguanide)
Number of subjects: 6
Study 7382828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30041173 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific dual-task training (walking and counting)
Number of subjects: 105
Study 30041173 — intervention group
Group type: COMPARATOR
Intervention: Control group (unspecific low-intensity exercise)
Number of subjects: 105
Study 30672195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of Hegu needling and Shu needling techniques at the positive reaction points
Number of subjects: 90
Study 30672195 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture therapy
Number of subjects: 90
Study 25694350 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/d vitamin D3
Number of subjects: 76
Study 25694350 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/d vitamin D3
Number of subjects: 76
Study 25694350 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU/d vitamin D3
Number of subjects: 76
Study 25694350 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D3
Number of subjects: 76
Study 25694350 — intervention group
Group type: COMPARATOR
Intervention: 0 IU/d vitamin D3 (placebo)
Number of subjects: 76
Study 25239718 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group (audit and feedback intervention for frontline nurses)
Number of subjects: 13499
Study 25239718 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 13499
Study 25239718 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group
Number of subjects: 13499
Study 25239718 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 13499
Study 22966164 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong active elderly
Number of subjects: 24
Study 22966164 — intervention group
Group type: COMPARATOR
Intervention: Lifelong sedentary elderly
Number of subjects: 24
Study 22966164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine infusion
Number of subjects: 24
Study 20456484 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP, 500 microg b.i.d)
Number of subjects: 9
Study 20456484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 17507322 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 800 mg bid
Number of subjects: 199
Study 17507322 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 400 mg bid
Number of subjects: 199
Study 17507322 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 199
Study 16286387 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral corticosteroids (CS) used by 13 RA patients
Number of subjects: 42
Study 16286387 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid treatment (RA patients without CS and healthy controls)
Number of subjects: 42
Study 12401595 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fentanyl (10 micro g/kg bolus followed by 10 micro g. kg(‐1). h(‐1) infusion)
Number of subjects: 30
Study 12401595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (2 micro g/kg)
Number of subjects: 30
Study 12401595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IV and IT fentanyl protocols
Number of subjects: 30
Study 12401595 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl (10 micro g/kg bolus and 10 micro g. kg(‐1). h(‐1))
Number of subjects: 30
Study 12401595 — intervention group
Group type: COMPARATOR
Intervention: Combined IV and IT protocols
Number of subjects: 30
Study 12198783 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of colored target elements
Number of subjects: 0
Study 12198783 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of spatially distinct color word distractor
Number of subjects: 0
Study 12198783 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextually controlled skilled word recognition
Number of subjects: 0
Study 7885801 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of any (target-nontarget) difference in the display (heterogeneity/homogeneity decision)
Number of subjects: 0
Study 7885801 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of one potential source of difference (noncritical difference requiring a negative response)
Number of subjects: 0
Study 7885801 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance knowledge of the likely source of difference
Number of subjects: 0
Study 2297150 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol (Alupent inhalation solution)
Number of subjects: 41
Study 2297150 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 41
Study 364333 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 51
Study 364333 — intervention group
Group type: COMPARATOR
Intervention: Meglumine ioxithalamate
Number of subjects: 51
Study 364333 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 51
Study 6125394 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily doses of clobazam
Number of subjects: 114
Study 6125394 — intervention group
Group type: COMPARATOR
Intervention: Divided daily doses of clobazam
Number of subjects: 114
Study 31499563 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency PA breaks (HIGH-FREQ) consisting of 15 ×2 min bouts of moderate-intensity treadmill PA every 30 min
Number of subjects: 14
Study 31499563 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency PA breaks (LOW-FREQ) consisting of 3 ×10 min bouts of moderate-intensity treadmill PA every 180 min
Number of subjects: 14
Study 31499563 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting (SIT)
Number of subjects: 14
Study 31499563 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency PA breaks (LOW-FREQ)
Number of subjects: 14
Study 29576505 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod 2 mg once daily
Number of subjects: 1651
Study 29576505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1651
Study 29576505 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod
Number of subjects: 1651
Study 26909792 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoPredict (EP) test
Number of subjects: 536
Study 26909792 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 risk of recurrence (ROR) scores (ROR-S)
Number of subjects: 536
Study 26909792 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 risk of recurrence (ROR) scores (ROR-P)
Number of subjects: 536
Study 26909792 — intervention group
Group type: EXPERIMENTAL
Intervention: ROR-T (ROR-S, tumor size)
Number of subjects: 536
Study 26909792 — intervention group
Group type: EXPERIMENTAL
Intervention: ROR-PT (ROR-P, tumor size)
Number of subjects: 536
Study 26909792 — intervention group
Group type: EXPERIMENTAL
Intervention: EPclin (EP, tumor size, nodal status)
Number of subjects: 536
Study 25029702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy meal (3 servings providing 1350 mg calcium)
Number of subjects: 32
Study 25029702 — intervention group
Group type: COMPARATOR
Intervention: Control meal (no dairy)
Number of subjects: 32
Study 25029702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy meal
Number of subjects: 32
Study 22833447 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour of Battlemind Training module
Number of subjects: 1645
Study 22833447 — intervention group
Group type: COMPARATOR
Intervention: Survey-only control group
Number of subjects: 1645
Study 22833447 — intervention group
Group type: EXPERIMENTAL
Intervention: Battlemind Training module
Number of subjects: 1645
Study 19580368 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cyclosporine (ACsA) 300 mg, 3 days a week for 2 years
Number of subjects: 58
Study 19580368 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cyclosporine (ACsA)
Number of subjects: 58
Study 19580368 — intervention group
Group type: COMPARATOR
Intervention: Aerosol placebo
Number of subjects: 58
Study 19580368 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression (Novartis controls)
Number of subjects: 58
Study 16750618 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy with SM (15 mg/kg intramuscularly three times per week for the initial 3 months)
Number of subjects: 160
Study 16750618 — intervention group
Group type: COMPARATOR
Intervention: Combined chemotherapy without SM
Number of subjects: 160
Study 16750618 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy with SM
Number of subjects: 160
Study 16246987 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CrCl) of 30 mL/min or lower (<= 0.50 mL/s)
Number of subjects: 1005
Study 16246987 — intervention group
Group type: COMPARATOR
Intervention: Creatinine clearance (CrCl) higher than 90 mL/min (> 1.50 mL/s)
Number of subjects: 1005
Study 16246987 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with CrCl of 30 mL/min or lower (<= 0.50 mL/s)
Number of subjects: 1005
Study 16246987 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate kidney impairment (CrCl between 30 mL/min and 90 mL/min)
Number of subjects: 1005
Study 12172693 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg MDMA
Number of subjects: 8
Study 12172693 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg MDMA
Number of subjects: 8
Study 12172693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10444779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography guided puncture (UGP)
Number of subjects: 77
Study 10444779 — intervention group
Group type: COMPARATOR
Intervention: Anatomically oriented puncture (AOP)
Number of subjects: 77
Study 8545501 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotized state with whole-body catalepsy
Number of subjects: 15
Study 8545501 — intervention group
Group type: COMPARATOR
Intervention: Resting wakefulness
Number of subjects: 15
Study 2084208 — intervention group
Group type: EXPERIMENTAL
Intervention: TERM
Number of subjects: 144
Study 2084208 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard-TERM
Number of subjects: 144
Study 2084208 — intervention group
Group type: COMPARATOR
Intervention: Cavit
Number of subjects: 144
Study 2084208 — intervention group
Group type: COMPARATOR
Intervention: Cavit-G
Number of subjects: 144
Study 2084208 — intervention group
Group type: COMPARATOR
Intervention: Cavit-W
Number of subjects: 144
Study 2084208 — intervention group
Group type: COMPARATOR
Intervention: IRM-Caps
Number of subjects: 144
Study 2084208 — intervention group
Group type: COMPARATOR
Intervention: Dentemp
Number of subjects: 144
Study 504346 — intervention group
Group type: EXPERIMENTAL
Intervention: lithium sulphate (24‐36 mval/die)
Number of subjects: 24
Study 504346 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 30127049 — intervention group
Group type: EXPERIMENTAL
Intervention: 50*10^6 MSCs
Number of subjects: 20
Study 30127049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27034623 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g CrN (CrN-Low)
Number of subjects: 61
Study 27034623 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g CrN (CrN-High)
Number of subjects: 61
Study 27034623 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g CrM
Number of subjects: 61
Study 27034623 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 61
Study 26614627 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted cataract surgery
Number of subjects: 808
Study 26614627 — intervention group
Group type: COMPARATOR
Intervention: Manual phacoemulsification cataract surgery
Number of subjects: 808
Study 23686322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost-timolol fixed combination (BTFC)
Number of subjects: 41
Study 23686322 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 41
Study 20950386 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologically active salivary substitutes for 6 months
Number of subjects: 134
Study 20950386 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 134
Study 18830857 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg for 24 weeks
Number of subjects: 41
Study 18830857 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg and 8 mg)
Number of subjects: 41
Study 16647684 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day hormone free interval (HFI)
Number of subjects: 111
Study 16647684 — intervention group
Group type: COMPARATOR
Intervention: Continuing active pills
Number of subjects: 111
Study 16647684 — intervention group
Group type: EXPERIMENTAL
Intervention: 21/7-day pre-extension cycle with heavier daily flow ratings
Number of subjects: 111
Study 16647684 — intervention group
Group type: EXPERIMENTAL
Intervention: 21/7-day pre-extension cycle with lighter daily flow ratings
Number of subjects: 111
Study 14659770 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 4IU every other day for 3 months
Number of subjects: 12
Study 10716461 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 58
Study 9491200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dpt rush immunotherapy
Number of subjects: 14
Study 9491200 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study 8412148 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.32 ml/kg)
Number of subjects: 78
Study 8412148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 2951819 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (ipratropium bromide 40 mug and fenoterol 100 mug)
Number of subjects: 21
Study 2951819 — intervention group
Group type: COMPARATOR
Intervention: Berodual (ipratropium bromide 20 mug and fenoterol 50 mug)
Number of subjects: 21
Study 29228230 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 170
Study 29228230 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 170
Study 27469556 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 21
Study 27469556 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 21
Study 27469556 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT combined with aligners
Number of subjects: 21
Study 27469556 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 21
Study 25330837 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 75 mg daily for three consecutive menstrual cycles prior to IVF cycles
Number of subjects: 95
Study 25330837 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DHEA treatment)
Number of subjects: 95
Study 23194054 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with a blood glucose meter and 150 test strips
Number of subjects: 124
Study 23194054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMBG)
Number of subjects: 124
Study 23194054 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) after 1.5 years
Number of subjects: 124
Study 23194054 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with more than three measurements per week
Number of subjects: 124
Study 23194054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMBG) after 1.5 years
Number of subjects: 124
Study 20692119 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal suture anchors
Number of subjects: 110
Study 20692119 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable suture anchors
Number of subjects: 110
Study 18090035 — intervention group
Group type: EXPERIMENTAL
Intervention: Human placental extract (HPE)
Number of subjects: 100
Study 18090035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study 16700374 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with carbamazepine (Group A, n = 16)
Number of subjects: 50
Study 16700374 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with carbamazepine and phenytoin (Group B, n = 16)
Number of subjects: 50
Study 16700374 — intervention group
Group type: COMPARATOR
Intervention: No drugs (Group C, n = 18)
Number of subjects: 50
Study 16700374 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of congenital anomalies
Number of subjects: 50
Study 12853784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 1 gm twice daily
Number of subjects: 24
Study 12853784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10768339 — intervention group
Group type: EXPERIMENTAL
Intervention: Entoptic perimetry
Number of subjects: 104
Study 10768339 — intervention group
Group type: COMPARATOR
Intervention: Subjective impression
Number of subjects: 104
Study 10768339 — intervention group
Group type: COMPARATOR
Intervention: Amsler grid
Number of subjects: 104
Study 8888916 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 129
Study 8888916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk formula (CMF)
Number of subjects: 129
Study 8888916 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formula (CHF)
Number of subjects: 129
Study 8888916 — intervention group
Group type: COMPARATOR
Intervention: Family history of allergy
Number of subjects: 129
Study 1511608 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen
Number of subjects: 30
Study 1511608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6087129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-octapeptide (CCK-OP) treatment: 1 mg/ml solution, two drops, three times daily for one month
Number of subjects: 20
Study 6087129 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy flour treatment: 30 gm, three times daily for one month
Number of subjects: 20
Study 6087129 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CCK-OP and soy flour treatments
Number of subjects: 20
Study 6087129 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin-pancreozymin test
Number of subjects: 20
Study 6087129 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and bicarbonate secretion
Number of subjects: 20
Study 30713022 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing with follitropin delta
Number of subjects: 1326
Study 30713022 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing with follitropin alfa
Number of subjects: 1326
Study 30055373 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating scale model (interval scale)
Number of subjects: 2752
Study 30055373 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded response model (no interval scale, ordered response categories)
Number of subjects: 2752
Study 30055373 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial credit model (no interval scale)
Number of subjects: 2752
Study 30055373 — intervention group
Group type: EXPERIMENTAL
Intervention: Response categories associated with less pain
Number of subjects: 2752
Study 30055373 — intervention group
Group type: EXPERIMENTAL
Intervention: Response categories associated with low pain intensity
Number of subjects: 2752
Study 30055373 — intervention group
Group type: EXPERIMENTAL
Intervention: Response categories associated with high pain intensities
Number of subjects: 2752
Study 30055373 — intervention group
Group type: EXPERIMENTAL
Intervention: Smallest response categories
Number of subjects: 2752
Study 27115241 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated hearing loss (five degrees of hearing loss)
Number of subjects: 125
Study 27115241 — intervention group
Group type: COMPARATOR
Intervention: Normal hearing (control group)
Number of subjects: 125
Study 24861828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral 17β-estradiol (0.5 mg/d)
Number of subjects: 339
Study 24861828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose venlafaxine hydrochloride extended release (75 mg/d)
Number of subjects: 339
Study 24861828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 22192960 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 73
Study 22192960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 20185000 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) in patients with BMI <30 kg/m²
Number of subjects: 1231
Study 20185000 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) in patients with BMI >=30 kg/m²
Number of subjects: 1231
Study 20185000 — intervention group
Group type: COMPARATOR
Intervention: BMI <30 kg/m²
Number of subjects: 1231
Study 20185000 — intervention group
Group type: COMPARATOR
Intervention: BMI decrease
Number of subjects: 1231